Bionomics Investor Presentation Deck
MOU for BNC210 and MDMA Derivative (EMP-01) for Post-Traumatic Stress Disorder
Joint Feasibility Assessment with:
EmpathBio
EMP-01 = 3,4-Methylenedioxymethamphetamine
(MDMA) derivative
Bionomics
ATAI
LIFE
SCIENCES
DAILY NEWS
Word - Business Finance Lifestyle Travel Sport Weather
22 February 2021
●
●
●
Memorandum of Understanding
with EmpathBio's MDMA Derivative
Illustrative
Initial collaborative framework of preclinical studies to collectively explore a
combination drug treatment regimen with BNC210 and EMP-01
MDMA-assisted psychotherapy has demonstrated significant symptom
improvement in PTSD patients
FDA has granted a Breakthrough Therapy designation to MDMA-assisted
psychotherapy
EmpathBio is developing MDMA derivatives that may permit the entactogenic
effects of MDMA to be separated from some of the known adverse effects
To explore the possibility of a combination treatment regimen warranting
clinical evaluation
22View entire presentation